EUVIMEDEUVIMED entdecken
BeobachtungsstudieMultizentrische StudieOpen Access

Real‐World Effectiveness and Safety of Concizumab Prophylaxis in Hemophilia: Results From a National French Cohort

Caroline Galeotti, Antoine Rauch, Helene Gatti, Stephanie Desage, Alexandre Butelet, Christine Biron-Andreani, Sophie Susen, Roseline d'Oiron, Guillaume Chanteau, Valerie Proulle, Yesim Dargaud

Haemophilia · 2026

DOI: 10.1111/hae.70290 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift Haemophilia, 2026. Verfasst von Caroline Galeotti und 10 weiteren Autor:innen. Beteiligte Einrichtung: Centre De Référence de L'hémophilie Et Des Maladies Hémorragiques Rares, Hôpital Bicêtre, Université Paris-Saclay, Le KremlinBicêtre, France. Hauptthemen laut MEDLINE: Hemophilia A, Antibodies, Monoclonal, Humanized, Hemophilia B. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 21 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Inhibition of tissue factor pathway inhibitor represents an advanced rebalancing strategy for hemophilia, applicable across hemophilia A and B irrespective of inhibitor status. Although concizumab has demonstrated efficacy in clinical trials, real‐world data remain very limited.

Objectives

To evaluate the real‐world effectiveness and safety of concizumab prophylaxis in an unselected national cohort of patients treated in routine clinical practice in France.

Methods

This cross‐sectional observational study included all patients receiving concizumab through compassionate‐use or Early Access Programs across six French hemophilia centers. Retrospective data were collected from treatment initiation to a predefined cutoff (1, December 2025). Outcomes included bleeding rates, target joint status, surgical management, laboratory monitoring practices, adherence, and adverse events.

Results

Eleven patients were included, ten with hemophilia B with inhibitors and one with hemophilia B without inhibitors. Mean exposure to concizumab was 22.8 months. Compared with the pre‐treatment period, concizumab prophylaxis was associated with a marked reduction in bleeding, including complete absence of bleeding in four patients and resolution of target joints in nine of ten patients. Nine surgical procedures, including two major surgeries, were performed under concizumab prophylaxis with concomitant rFVIIa without thrombotic complications. No thrombotic events or injection‐site pain were reported. None of the patients discontinued concizumab prophylaxis.

Conclusions

In this nationwide real‐world cohort, concizumab prophylaxis was effective, well tolerated, and manageable in routine practice, including during surgical procedures. These data support its use as a valuable prophylactic option in carefully selected patients with hemophilia B and inhibitors, while underscoring the importance of individualized monitoring and thrombotic risk assessment.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Hemophilia AAntibodies, Monoclonal, HumanizedHemophilia BHumansFranceMaleAdultCross-Sectional StudiesAdolescentRetrospective StudiesTreatment OutcomeYoung AdultFemaleHemorrhageChildCohort StudiesMiddle AgedChild, Preschool

Stichwörter der Autor:innen

anti‐TFPI antibodyconcizumabhemophiliahemophilia Binhibitorsrebalancing agents

Substanzen

Antibodies, Monoclonal, Humanizedconcizumab

Autor:innen und Institutionen

  • Centre De Référence de L'hémophilie Et Des Maladies Hémorragiques Rares, Hôpital Bicêtre, Université Paris-Saclay, Le KremlinBicêtre, France.
  • Hématologie-transfusion, CHU De Lille, Lille, France.
  • Service De Pédiatrie, Hopital Taaone, Pirae, Polynesie Francaise.
  • Centre De Reference de L'hemophilie - Unite d'Hemostase Clinique, Hopital Louis Pradel Et UR4609 Hemostase & Thrombose Universite Lyon 1, Lyon, France.
  • Service Hématologie Biologique, UF Hémostase clinique, Hôpital Robert, Debré, CHU Reims, France.
  • Centre De Ressources et De Compétences - Maladies Hémorragiques rares, Service D'hématologie Biologique, CHU De Montpellier, Montpellier, France.

Zitieren

APA

Galeotti, C., Rauch, A., Gatti, H., Desage, S., Butelet, A., Biron-Andreani, C., Susen, S., d'Oiron, R., Chanteau, G., Proulle, V., & Dargaud, Y. (2026). Real‐World Effectiveness and Safety of Concizumab Prophylaxis in Hemophilia: Results From a National French Cohort. Haemophilia. https://doi.org/10.1111/hae.70290

Vancouver

Galeotti C, Rauch A, Gatti H, Desage S, Butelet A, Biron-Andreani C, et al. Real‐World Effectiveness and Safety of Concizumab Prophylaxis in Hemophilia: Results From a National French Cohort. Haemophilia. 2026. doi:10.1111/hae.70290

BibTeX
@article{Galeotti2026,
  author = {Galeotti, Caroline and Rauch, Antoine and Gatti, Helene and Desage, Stephanie and Butelet, Alexandre and Biron-Andreani, Christine and Susen, Sophie and d'Oiron, Roseline and Chanteau, Guillaume and Proulle, Valerie and Dargaud, Yesim},
  title = {Real‐World Effectiveness and Safety of Concizumab Prophylaxis in Hemophilia: Results From a National French Cohort},
  journal = {Haemophilia},
  year = {2026},
  doi = {10.1111/hae.70290}
}
Kostenlos starten →